AAP
ESPR

Arax Advisory Partners’s Esperion Therapeutics ESPR Stock Holding History

Arax Advisory Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107 Buy
+34
New +$95 ﹤0.01% 5134
2026
Q1 		– Sell
-15
Closed -$56 – 3969
2025
Q4 		$56 Sell
15
-7,735
-100% -$25K ﹤0.01% 3905
2025
Q3 		$20.5K Buy
+7,750
New +$15K ﹤0.01% 2254

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Arax Advisory Partners's ESPR Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 34 shares worth $107. The stake represents ﹤0.01% of the portfolio and ranks #5134 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in ESPR as recently as Q4 2025.

Arax Advisory Partners first reported a position in ESPR in Q3 2025 and has held it in 3 quarters since. The position peaked at $20.5K in Q3 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Arax Advisory Partners held 34 shares of Esperion Therapeutics worth $107 as of Q2 2026.
  • Esperion Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5134 holding.
  • Arax Advisory Partners first reported a position in Esperion Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Esperion Therapeutics position peaked at $20.5K in Q3 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.